Lipoflex Special Sin Electrolitos

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serine, the active ingredients in Lipoflex Special Sin Electrolitos, are amino acids presented as an intravenous solution for parenteral nutrition use. It provides essential and non‑essential amino acids to support protein synthesis and metabolic functions in patients who cannot receive enteral feeding.

GNH USA supplies Lipoflex Special Sin Electrolitos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lipoflex Special Sin Electrolitos is used in parenteral nutrition to deliver a balanced amino acid profile for patients requiring intravenous feeding. - Parenteral nutrition: supplies essential and non‑essential amino acids to maintain nitrogen balance and support protein synthesis. - Critical illness: provides metabolic support for patients with severe trauma or sepsis who cannot tolerate oral intake. - Post‑operative recovery: aids tissue repair and wound healing during postoperative intravenous feeding.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels during infusion. - Electrolyte imbalance: changes in serum potassium, sodium, or calcium. - Phlebitis: irritation or inflammation at the infusion site. - Nausea: feeling of queasiness during or after administration. - Vomiting: expulsion of stomach contents following infusion.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Metabolic acidosis: accumulation of acid in the blood due to altered metabolism. - Renal dysfunction: impaired kidney function potentially exacerbated by high nitrogen load.

Before initiating therapy, clinicians should assess patient-specific factors and monitor relevant parameters. - Renal impairment: monitor serum creatinine and adjust infusion rate as needed. - Hepatic dysfunction: evaluate liver function tests and consider dose modification. - Electrolyte disorders: check serum electrolytes before and during treatment. - Hyperammonemia risk: monitor ammonia levels in patients with urea cycle disorders. - Allergy: discontinue infusion if signs of hypersensitivity appear. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amino acid solutions may interact with other intravenous therapies and metabolic agents. Major Interactions (Avoid): - Concurrent high‑dose amino acid solutions: risk of excess nitrogen load. - Incompatible IV solutions containing calcium or phosphate: precipitation risk. Moderate Interactions (Monitor Closely): - Insulin therapy: may require dose adjustment due to glucose fluctuations. - Diuretics: monitor electrolyte shifts during combined use. - Renal replacement therapy: may alter amino acid clearance and require dosing review.